Developer deep dive: Designing proteins and reagents for cell and gene therapy research
23 Aug 2021

Recombinant proteins require strict quality control, as quality issues affect the reliability of the intended downstream application. Cell and gene therapy research in particular demands a higher quality of protein that adheres to strict quality control and has comprehensive validation.

In this exclusive SelectScience® webinar, Dr. Deborah Moore-Lai, Director of Protein Development at Abcam, will introduce a new range of premium bioactive proteins. During the session, Moore-Lai will be detailing Abcam’s manufacturing workflow, as well as outlining the company’s mission to support scientists in achieving their goals in cell and gene therapy research and other research areas.

Key learning objectives

  • Discover and understand Abcam’s new product range, including the new premium bioactive proteins
  • Learn how Abcam’s premium bioactive proteins can support your research
  • Understand the manufacturing workflow for producing bioactive proteins

Who should attend

Scientists interested in learning more about how Abcam can support their research through the development and supply of high-quality, bioactive proteins.

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary for continuing education purposes.

Speaker name: Dr. Deborah Moore-Lai, Director of Protein Development, Abcam

Professional bio: Deborah Moore-Lai joined Abcam in 2019 to lead the new Proteins Initiative, which included building out a new laboratory space and recruiting a new team of scientists with skills in protein expression, purification, and assay development. Before joining Abcam, Deborah spent 16 years working in industry in both the reagent and therapeutic spaces. For many years, she led the Antibody Production team at Cell Signaling Technology. From there Deborah joined Merck Research Laboratories, where she led the team responsible for antigen and antibody generation within Biologics Discovery.

Abcam plc